Why NMOSD is so serious<\/h2>\n\n\n\n
Neuromyelitis optica spectrum disorder, often shortened to NMOSD, can cause sudden vision loss, painful spasms, weakness, paralysis, vomiting, hiccups, and bladder or bowel problems. <\/p>\n\n\n\n
Read More: Colon cancer can appear through symptoms people dismiss, and the silent window is what makes early warning signs so dangerous<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nThe National Institute of Neurological Disorders and Stroke describes it as a disorder in which the immune system damages parts of the central nervous system, especially the optic nerves and spinal cord.<\/p>\n\n\n\n
For patients, that can mean much more than a diagnosis on paper. A relapse can change daily life quickly, from reading a phone screen to walking across a room or using the bathroom without help. That is why preventing attacks matters so much.<\/p>\n\n\n\n
A full immune reset<\/h2>\n\n\n\n
The treatment used in this report is called an allogeneic hematopoietic<\/a> stem cell transplant. In plain English, doctors try to replace a patient\u2019s faulty blood-forming immune system with healthy stem cells from a donor.<\/p>\n\n\n\nGiorgio Orofino, Angela Genchi, Maria Teresa Lupo Stanghellini, and colleagues reported the long-term results in a new case report. Their work tracked two patients whose NMOSD had not responded to standard treatment.<\/p>\n\n\n\n
Before the donor cells were given, the patients received chemotherapy drugs to clear out malfunctioning immune cells. They also received rituximab, a monoclonal antibody that reduces B cells, the immune cells that can make harmful antibodies.<\/p>\n\n\n\n
What doctors saw<\/h2>\n\n\n\n
The key antibody in this story is called AQP4-IgG<\/a>. In many people with NMOSD, it mistakenly targets support cells in the nervous system, setting off inflammation that can damage the protective coating around nerve fibers<\/a>.<\/p>\n\n\n\nAfter the transplant, that antibody became undetectable in both patients and stayed that way through the long follow-up. Doctors also used neurological exams, brain and spinal cord MRI scans, and antibody testing to monitor what happened over the next 15 and 16 years.<\/p>\n\n\n\n
\n\n\nRead More: Jeremy Clarkson\u2019s prostate cancer diagnosis puts a common male screening problem back in front of millions of viewers<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nThe patients also reported better quality of life. One saw major improvement in physical ability and later became a father of two children, while the other still had disability from earlier damage but could do some activities that had once been out of reach.<\/p>\n\n\n\n
Why 15 years matters<\/h2>\n\n\n\n
Many NMOSD treatments aim to reduce relapse risk<\/a> by calming or blocking parts of the immune system. That can be lifesaving, but it usually means ongoing therapy and careful follow-up.<\/p>\n\n\n\n![\"A](\"https:\/\/okdiario.com\/metabolic\/en\/wp-content\/uploads\/2026\/07\/neuromyelitis-optica-stem-cell-transplant-study-1.jpg\" "\\"\\"")
After receiving donor stem cell transplants, two patients with treatment-resistant NMOSD achieved over 15 years of relapse-free health.<\/figcaption><\/figure>\n\n\n\nThis report points to something different. For these two selected patients, the transplant did not just hold attacks down for a short period, it appeared to rebuild the immune system in a way that removed the disease-linked antibody from the blood.<\/p>\n\n\n\n
That is a big reason the 15-year window stands out. Earlier research on autologous stem cell transplantation, which uses a patient\u2019s own cells, found relapse-free survival of 31% at three years and 10% at five years in a group of 16 refractory NMO patients.<\/p>\n\n\n\n
Not a routine treatment<\/h2>\n\n\n\n
Still, this is not a simple new cure that can be handed to every patient. It is a report of two people, both with unusually severe disease, and that kind of evidence can show possibility but cannot prove broad safety or benefit.<\/p>\n\n\n\n
Allogeneic stem cell transplant also carries serious risks. The National Cancer Institute notes that even with prevention, up to half of people receiving this kind of transplant may develop graft-versus-host disease<\/a>, a complication in which donor immune cells attack the patient\u2019s healthy tissues.<\/p>\n\n\n\n\n\n\nRead More: Chemotherapy tries to break tumor DNA, but one protein may help cancer cells repair the damage and survive treatment<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nThat risk changes the conversation. A treatment like this would likely be considered only for carefully selected patients, especially when other options have failed and the disease itself is causing major danger.<\/p>\n\n\n\n
What comes next<\/h2>\n\n\n\n
The most careful takeaway is not hype, but proof of concept. The cases suggest that, in rare circumstances, replacing the immune system<\/a> may deeply change the course of NMOSD instead of only suppressing it.<\/p>\n\n\n\nWhat would doctors need next? Larger studies, longer safety tracking, and clearer rules for who might benefit enough to justify the risk. That is the hard part.<\/p>\n\n\n\n
For families facing repeated relapses, though, the report offers a reason to watch this field closely. <\/p>\n\n\n\n
The main study has been published in Med<\/a><\/em>.<\/p>\n","protected":false},"excerpt":{"rendered":"Have you ever heard of an illness where the immune system turns on the nerves that help you see and … <\/p>\n
Giorgio Orofino, Angela Genchi, Maria Teresa Lupo Stanghellini, and colleagues reported the long-term results in a new case report. Their work tracked two patients whose NMOSD had not responded to standard treatment.<\/p>\n\n\n\n
Before the donor cells were given, the patients received chemotherapy drugs to clear out malfunctioning immune cells. They also received rituximab, a monoclonal antibody that reduces B cells, the immune cells that can make harmful antibodies.<\/p>\n\n\n\n
What doctors saw<\/h2>\n\n\n\n
The key antibody in this story is called AQP4-IgG<\/a>. In many people with NMOSD, it mistakenly targets support cells in the nervous system, setting off inflammation that can damage the protective coating around nerve fibers<\/a>.<\/p>\n\n\n\n After the transplant, that antibody became undetectable in both patients and stayed that way through the long follow-up. Doctors also used neurological exams, brain and spinal cord MRI scans, and antibody testing to monitor what happened over the next 15 and 16 years.<\/p>\n\n\n\n The patients also reported better quality of life. One saw major improvement in physical ability and later became a father of two children, while the other still had disability from earlier damage but could do some activities that had once been out of reach.<\/p>\n\n\n\n Many NMOSD treatments aim to reduce relapse risk<\/a> by calming or blocking parts of the immune system. That can be lifesaving, but it usually means ongoing therapy and careful follow-up.<\/p>\n\n\n\n This report points to something different. For these two selected patients, the transplant did not just hold attacks down for a short period, it appeared to rebuild the immune system in a way that removed the disease-linked antibody from the blood.<\/p>\n\n\n\n That is a big reason the 15-year window stands out. Earlier research on autologous stem cell transplantation, which uses a patient\u2019s own cells, found relapse-free survival of 31% at three years and 10% at five years in a group of 16 refractory NMO patients.<\/p>\n\n\n\n Still, this is not a simple new cure that can be handed to every patient. It is a report of two people, both with unusually severe disease, and that kind of evidence can show possibility but cannot prove broad safety or benefit.<\/p>\n\n\n\n Allogeneic stem cell transplant also carries serious risks. The National Cancer Institute notes that even with prevention, up to half of people receiving this kind of transplant may develop graft-versus-host disease<\/a>, a complication in which donor immune cells attack the patient\u2019s healthy tissues.<\/p>\n\n\n\n That risk changes the conversation. A treatment like this would likely be considered only for carefully selected patients, especially when other options have failed and the disease itself is causing major danger.<\/p>\n\n\n\n The most careful takeaway is not hype, but proof of concept. The cases suggest that, in rare circumstances, replacing the immune system<\/a> may deeply change the course of NMOSD instead of only suppressing it.<\/p>\n\n\n\n What would doctors need next? Larger studies, longer safety tracking, and clearer rules for who might benefit enough to justify the risk. That is the hard part.<\/p>\n\n\n\n For families facing repeated relapses, though, the report offers a reason to watch this field closely. <\/p>\n\n\n\n The main study has been published in Med<\/a><\/em>.<\/p>\n","protected":false},"excerpt":{"rendered":" Have you ever heard of an illness where the immune system turns on the nerves that help you see and … <\/p>\nRead More: Jeremy Clarkson\u2019s prostate cancer diagnosis puts a common male screening problem back in front of millions of viewers<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
Why 15 years matters<\/h2>\n\n\n\n
Not a routine treatment<\/h2>\n\n\n\n
Read More: Chemotherapy tries to break tumor DNA, but one protein may help cancer cells repair the damage and survive treatment<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
What comes next<\/h2>\n\n\n\n